Market Overview

UPDATE: Credit Suisse Initiates Infinity Pharmaceuticals at Outperform on Risk/Reward

Related INFI
Infinity Announces Clinical And Preclincal Data For Duvelisib To Be Presented at ASH 2014 Annual Meeting
Infinity Reports Topline Data From Phase 2a Exploratory Study Of Duvelisib In Patients With Mild, Allergic Asthma

Credit Suisse initiated coverage on Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) with a Outperform rating and a $42.00 price target.

Credit Suisse commented, "We believe that the next steps in the development of IPI-145 are lower risk than typical for a drug at its stage, and expect IPI-145 to emerge as a best-in-class PI3K inhibitor. We also view the target markets as able to support several multibillion dollar drugs, and expect that IPI-145 could capture a meaningful share. While higher risk, earlier stage, and less investible than its larger pier PCYC, we believe that risk/reward for INFI remains favorable."

Infinity Pharmaceuticals closed at $32.93 on Monday.

Latest Ratings for INFI

DateFirmActionFromTo
Dec 2014Credit SuisseUpgradesNeutralOutperform
Nov 2014NomuraMaintainsNeutral
Oct 2014Stifel NicolausInitiates Coverage onHold

View More Analyst Ratings for INFI
View the Latest Analyst Ratings

Posted-In: Credit SuisseAnalyst Color Initiation Intraday Update Analyst Ratings

 

Related Articles (INFI)

Around the Web, We're Loving...

Get Benzinga's Newsletters